Humacyte reports Q1 EPS (9c), consensus (12c)

Reports Q1 revenue $495,000, consensus $1.46M. “We have seen expansion in the commercial uptake of Symvess. We also recognize that more rapid growth and expansion of sales is necessary and warranted, based on this innovative product’s potential,” said Laura Niklason, founder and CEO of Humacyte (HUMA). “Therefore, as recently announced, we have made substantial hires in senior commercial and surgical leadership positions including industry veteran James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer. Jim is an accomplished medtech commercial leader with an extensive track record of field-specific success in vascular and cardiothoracic surgery markets. Dr. Rasmussen is one of the trailblazers of modern vascular surgery and will be instrumental in guiding scientific strategy and real-world implementation of Symvess going forward. We look forward to working with both of our new leaders to accelerate and expand patient access to Symvess.”